Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methadone conversion strategies for refractory cancer pain in patients on high-dose opioids
ChiCTR2400085332Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methadone in cancer pain (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Time to stable analgesia, Methadone conversion efficiency and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
methadone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2400085332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085332.